All News
Drug retention rates & treatment outcomes in 1,860 axSpA patients Rx with secukinumab in routine clinical practice in 13 European countries in the EuroSpA research collaboration network -> registry data drug retention rates THU0398 @RheumNow #EULAR2020 https://t.co/x3Y4tMetij https://t.co/DkUyIfyWwS
Links:
Dr Philip Robinson philipcrobinson ( View Tweet)
The Relative Diagnostic Utility of inflamm back pain criteria in inception cohort with PsO, Iritis, & Colitis Presenting With Undiagnosed Back Pain: All IBP criteria have poor diagnostic utility for dx of axSpA, esp in PsO Abs SAT0378 #EULAR2020 @RheumNow https://t.co/Y7sbtJtm3U https://t.co/P9q7uJozZ9
Links:
Dr Philip Robinson philipcrobinson ( View Tweet)
Filgotinib was associated with significant reduction in SIJ erosion scores in axSpA: imaging data from the double-blind, randomized Tortuga trial #EULAR2020 @rheumnow THU0377 https://t.co/1b18Uyvo5j https://t.co/zBXCwGc0Q7
Links:
Dr Philip Robinson philipcrobinson ( View Tweet)
Replacing radiographic sacroiliitis with MRI structural damage doesn't change the classifciation of axSpA signifciantly @RheumNow #EULAR2020 Abstract SAT0384 https://t.co/MTTf4fHjYT
Dr Philip Robinson philipcrobinson ( View Tweet)
Preliminary definition of a +MRI for struc lesions in the SIJs in axSpA: Erosion in ≥2 consec slices or in ≥3 SIJ quad and fat lesion w depth >1cm in ≥1 SIJ quad are high priority for def an MRI struc lesion of axSpA. Abs OP0079 #EULAR2020 @RheumNow https://t.co/9RlSOUviJQ https://t.co/l4XiQDj8e4
Links:
Dr Philip Robinson philipcrobinson ( View Tweet)
Secukinumab in nr-axSpA, in a mostly biologic naive cohort was effective: ASAS40 response of ~42%, data from the Phase III prevent trial Abstract OP0106 #EULAR2020 @rheumnow https://t.co/KATpGJs2y9 https://t.co/zeBFS2pMl0
Links:
Dr Philip Robinson philipcrobinson ( View Tweet)
#Eular2020 #op0224 filgotinib successfully reduces levels of circulating biomarkers in PsA suggestive of clinical efficacy: CRP&SAA >50%, IL6, CXCL10&IL23 >25%. Also decreased ICAM1,VCAM1, MMP1&SC1M @RheumNow
Olga Petryna DrPetryna ( View Tweet)
#EULAR2020 ABST#OP0014 Plenary session: Secukinumab and etanercept do NOT work for anterior uveitis in SpA based on Swedish Rheum Quality Registry of > 2600 patients @rheumnow https://t.co/2kJ3b4JObq
k dao KDAO2011 ( View Tweet)
#EULAR2020 Abstr#LB001 Coming soon...another indication for @Rinvoq? Favorable response in phase III trial of upadacitinib vs. ADA vs. PCB for PsA (SELECT-PsA-1) @abbvie @rheumnow https://t.co/0udmPlR2pQ
k dao KDAO2011 ( View Tweet)
#EULAR2020 Dr. Kimme Hyrich reviews the EULAR #COVID19 Registry "Most individuals with rheumatic diseases receiving immunosuppressive therapies recover from COVID19" @rheumnow https://t.co/EdVLUMyHhF
k dao KDAO2011 ( View Tweet)
A study worth remembering. Pts with FM-PsA had statistically higher PsA dz activity in subjective measures ONLY, not in objective measures. Make sure you take time to fully treat your patients and give them tools for FM as well as PsA. #EULAR2020 @RheumNow #AB0731 https://t.co/e3JkEmq3EZ
Dr. Rachel Tate uptoTate ( View Tweet)
SELECT-PSA-2 results: UPA15 & UPA30 showed improvement across PsA domains vs PBO through Wk 24. No new safety signals were identified. Check out abstract #OP0223 for the MDA/ACR50/ACR70 responses. #EULAR2020 @RheumNow https://t.co/UAx2tkKSZI
Dr. Rachel Tate uptoTate ( View Tweet)
Do you use different medications for different PsA domains? Teach me how you practice! #EULAR2020 @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
Study out of Switzerland finds lower response rates to TNFi in women with nr-axSpA vs men. Poster #THU0383 #EULAR2020 @RheumNow https://t.co/uWNqwqamQM https://t.co/pgnhCaw9f6
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
Interestingly, first line use was the only predictor of improved retention of SEC in axSpA patients in this French study. Poster #THU0386 #EULAR2020 @RheumNow https://t.co/keI9xGWKCL https://t.co/avLtJzaEOc
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
This Spanish study of 255 SpA pts found that acute unilateral anterior uveitis was the most common pattern, primarily in HLA B27+. NO difference in incidence between SEC and TNFi treated pts. #EULAR2020 @RheumNow Poster #THU0388 https://t.co/OMfG8atfE4
Dr. Rachel Tate uptoTate ( View Tweet)
This Turkish study found that obesity did NOT play a roll in tx efficacy/retention using SEC in axSpA patients. #EULAR2020 Poster #THU0390 @RheumNow https://t.co/z3imYNuxYq https://t.co/sGz9cohH6T
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
nr-axSpA pts with active inflammation improved with IXE. Drug efficacy did not change in pts with elevated CRP or sacroiliitis or both. #EULAR2020 @RheumNow poster #THU0395 https://t.co/ap6Wy2eNBL https://t.co/zLoNHuSVV5
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
COAST-V and COAST-X trial results: Both TNFi experienced and naive AS pts had better work productivity compared to PBO. #EULAR2020 @RheumNow poster #THU0396
https://t.co/UPDpLqCSkG https://t.co/UTLzxxTG8K
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
Interesting abstract #ABO113, out of Germany found that H. Pylori ab p66-UreB, p29-UreA, and p54-flagelin are more prominent in PsA/PsO pts. Another suggested potential link to the gut microbiome and dz? Hopefully, more data to come. #EULAR2020 @RheumNow https://t.co/mQRhsmgsHw
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
